Dr. Hassan Bukhari, Dr. Nosheen Ahmad, Dr. Irfan Shabbir, Dr. Ibrahim Nasir Idrees



A Descriptive cross-sectional study was conducted in the Department of Radiology Allied Hospital, Faisalabad from August 2014 to June 2015 to detect the diagnostic Accuracy of Magnetic Resonance Spectroscopy (MRS) In Malignant Breast Lesions using histopathology as gold standard.

Materials & Methods:          

A total of 110 patients with breast lesions on ultrasound (US) and on mammography and age 20-60 years were included. Patients who took chemotherapy for primary or secondary breast cancer, pregnant or breast feeding females, patients with renal failure and contraindication to MRS were excluded. All the patients were then underwent MRS on 1.5 tesla whole body MR imager. Breast lesion was considered as malignant if there was choline peak on magnetic resonance spectroscopy and choline/creatine ratio was >1.5. Magnetic resonance spectroscopy findings were correlated with histopathological findings.


Mean age was 49.31 ± 6.76 years. MRS supported the diagnosis of malignant breast lesions in 72 (65.45%) patients. Histopathology confirmed malignancy in 75 (68.18%) cases. In 72 MRS positive patients, 68 were True Positive and 04 were False Positive. Among, 38 MRS negative patients, 07 were False Negative whereas 31 were True Negative. Overall sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of MRS in malignant breast lesions was 90.67%, 88.57%, 94.44%, 81.58% and 90.0% respectively.


This study concluded that magnetic resonance spectroscopy is a highly sensitive and accurate modality for diagnosing malignant breast lesions, and has improved patient care by accurate and timely diagnosis for taking proper treatment options.

Full Text:



Buccimazza I. Approach to the diagnosis of a breast lump. Continue Med Edu. 2010;23(11):515-8.

Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;1:1877.

Sariego J. "Breast cancer in the young patient". Am Surg. 2010;76(12):1397–401.

Jemal A, Bray F, Centre MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Ca Cancer J Clin. 2011;61:69–90.

Jemal A, Center MM, Desantis C, Ward EM. Global patterns of cancer incidence andmortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893-907.

Turnbull LW. Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed. 2009;22(1):28-39.

Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307:1394-404.

Basara I, Orguc S, Coskun T. Single voxel in vivoproton magnetic resonance spectroscopy of breast lesions: experience in 77 cases. Diagn Interv Radiol. 2013;19:221–26.

Shafqat G, Masror I, Rehan M, Afzal S. Dynamic contrast enhanced MRI breast for lesion detection and characterization with histopathological co relation: Preliminary experience at tertiary care hospital. J Pak Med Assoc. 2011;61:252.

Begley JKP, Redpath TW, Bolan PJ, Gilbert FJ. In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature. Breast Cancer Res. 2012;14:207.

Baek HM. Diagnostic Value of Breast Proton Magnetic Resonance Spectroscopy at 1.5T in Different Histopathological Types. SciWorld J. 2012;2012:1-8.

12,Maskarinec G, Meng L, Ursin G. Ethnic differences in mammographic densities. Int J Epidemiol. 2001;30:959–65.

13.Saarenmaa I, Salminen T, Geiger U. The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultrasonography. Breast Cancer Res Treat. 2001;67:117–23.

Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology. 1995;196:123–34.

Jackson VP. The current role of ultrasonography in breast imaging. Radiol Clin North Am. 1995;33:1161–170.

Duncan JL III, Cederbom GJ, Champaign JL. Benign diagnosis by image-guided core-needle breast biopsy. Am Surg. 2000;66:5–10.

Chiou SY, Chou YH, Chiou HJM, et al. Sonographic features of nonpalpable breast cancer: a study based on ultrasound- guided wire-localized surgical biopsies. Ultrasound Med Biol. 2006;32:1299–306.

Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiol. 1998;209(1):269–75.

Kvistad KA, Bakken IJ, Gribbestad IS. Characterization of neoplastic and normal human breast tissues with in vivo 1H MR spectroscopy. J Magnetic Resonance Imaging. 1999;10(2):159–64.

Jagannathan NR, Kumar M, Seenu V. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer. 2001;84(8):1016–22.

American Cancer Society. Breast Cancer Facts & Figures 2011-2012. Available at http://www.cancer.org/Research/CancerFactsFigures/BreastCancerFactsFigures/breast-cancer-facts-and-figures-2011-2012. Accessed June 10, 2013.

Haddadin IS, Mclntosh A, Meisamy S. Metabolite quantification and high-field MRS in breast cancer. NMR in Biomed. 2009;22(1):65–76.

Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst. 2002;94(16):1197-203.

Meisamy S, Bolan PJ, Baker EH, Pollema MG, Le Chap T, Kelcz F, et al.. Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology. 2005;236(2):465-75.

Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vorbuchner M, Podo F. In Vivo Proton MR Spectroscopy of the Breast Using the Total Choline Peak Integral as a Marker of Malignancy. Am J Roentgenol. 2009;192:1608-617.

Bartella L, Morris EA, Dershaw DD, Liberman L, Thakur SB, Moskowitz C, et al. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology. 2006;239(3):686-92.

Brennan S, Thakur SB, Liberman L, Wei H, Morris EA, Dershaw DD, et al. Proton Magnetic Resonance Spectroscopy in Breast Disease. Paper presented at the 94th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from http://www.biowizard.com/cabs/mis_search.php?keyword=&author=&conference=:c95401&start=12/16/2007&end=1/16/2009


  • There are currently no refbacks.

© Copyright PJR 2008-